TOCA - トカジェン (Tocagen Inc.)

TOCAのニュース

   Tocagen Reports First Quarter 2020 Financial Results  2020/04/23 20:05:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a…
   Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results  2020/02/27 21:10:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of…
   Tocagen and Forte Biosciences Announce Merger  2020/02/20 01:13:00 PR Newswire
SAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they…
   HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA)  2019/11/14 15:14:27 Modern Readers
Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […]
   Tocagen Reports Third Quarter 2019 Financial Results and Business Updates  2019/11/12 21:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5…
   Tocagen Reports First Quarter 2020 Financial Results  2020/04/23 20:05:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a…
   Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results  2020/02/27 21:10:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of…
   Tocagen and Forte Biosciences Announce Merger  2020/02/20 01:13:00 PR Newswire
SAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they…
   HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA)  2019/11/14 15:14:27 Modern Readers
Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […]
   Tocagen Reports Third Quarter 2019 Financial Results and Business Updates  2019/11/12 21:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5…
   Tocagen Reports First Quarter 2020 Financial Results  2020/04/23 20:05:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a…
   Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results  2020/02/27 21:10:00 PR Newswire
SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of…
   Tocagen and Forte Biosciences Announce Merger  2020/02/20 01:13:00 PR Newswire
SAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they…
   HC Wainwright Reaffirms “Hold” Rating for Tocagen (NASDAQ:TOCA)  2019/11/14 15:14:27 Modern Readers
Tocagen (NASDAQ:TOCA)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. A number of other equities research analysts also recently weighed in on TOCA. Chardan Capital reissued a “hold” rating and set a $1.00 price target on shares of Tocagen in […]
   Tocagen Reports Third Quarter 2019 Financial Results and Business Updates  2019/11/12 21:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019. "Following the topline readout of our Phase 3 Toca 5…

calendar